Nine Masts Capital’s Revolution Medicines RVMD Stock Holding History

Nine Masts Capital’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,000	Closed	-$107K	–	277
2026 Q1	$107K	Buy	+11,000	New	+$1.11M	0.02%	126

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Nine Masts Capital's RVMD Position: Q2 2026 in Review

Nine Masts Capital sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 11,010 shares — an estimated $1.07M sold.

Nine Masts Capital first reported a position in RVMD in Q1 2026 and held it in 1 quarter. The position peaked at $1.07M in Q1 2026. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Nine Masts Capital reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 11,010 Revolution Medicines shares in Q2 2026, an estimated $1.07M.
Nine Masts Capital first reported a position in Revolution Medicines in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Revolution Medicines position peaked at $1.07M in Q1 2026.
691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.